FTHL17: A Drug Target / Disease Biomarker (G53940)
FTHL17: A Drug Target / Disease Biomarker
FTHL17, also known as FGF-17, is a protein that is expressed in various tissues throughout the body, including the skin, hair, and nails. It is a member of the fibroblast growth factor (FGF) family, which is a group of proteins that are involved in cell growth, differentiation, and repair.
Recent studies have identified FTHL17 as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because FTHL17 has been shown to play a role in the development and progression of these conditions, and may be a useful target for therapies that are aimed at reducing inflammation, promoting tissue repair, or inhibiting the growth of cancer cells.
One of the key mechanisms by which FTHL17 is thought to contribute to the development and progression of these diseases is its role in the regulation of cell proliferation. FTHL17 has been shown to promote the growth and proliferation of various types of cancer cells, including skin, breast, and prostate cancer cells. This may contribute to the development of new cancer treatments that focus on targeting FTHL17 and inhibiting its activity.
Another potential mechanism by which FTHL17 may contribute to the development and progression of these diseases is its role in the regulation of cellular differentiation. FTHL17 has been shown to promote the maintenance of stem cells, which are cells that have the ability to develop into any type of cell in the body. This may contribute to the development of diseases that are characterized by the overgrowth of stem cells, such as leukemia or solid tumors.
In addition to its role in cell proliferation and differentiation, FTHL17 has also been shown to play a role in the regulation of tissue repair and regeneration. FTHL17 has been shown to promote the growth of new tissue in response to injuries or other types of damage, which may be useful in the treatment of diseases that are characterized by tissue damage or regeneration disorders.
Finally, FTHL17 has also been shown to play a role in the regulation of cellular signaling processes that are involved in the development and progression of diseases. FTHL17 has been shown to interact with a variety of signaling pathways, including those that are involved in cell growth, differentiation, and inflammation. This may suggest that FTHL17 is involved in the regulation of cellular processes that are critical for the development and progression of these diseases.
Given the potential role of FTHL17 in the development and progression of these diseases, researchers are actively exploring new approaches to the treatment of these conditions. One of the most promising strategies is the use of small molecules, such as drugs that mimic the activity of FTHL17, to inhibit its activity and reduce the growth and proliferation of cancer cells.
Another approach to the treatment of diseases associated with FTHL17 is the use of antibodies, such as monoclonal antibodies (MCAs), which are laboratory-produced proteins that are designed to recognize and bind to specific proteins in the body. FTHL17 has been shown to be a target for some antibodies, and the use of MCAs that recognize FTHL17 may be a promising strategy for the treatment of diseases associated with this protein.
Overall, FTHL17 is a protein that has been shown to play a critical role in the development and progression of various diseases. The potential use of small molecules and antibodies that mimic or inhibit its activity makes it an attractive target for the development of new therapies aimed at treating these conditions. Further research is needed to fully understand the role of FTHL17 in the development and progression of these diseases, and to develop effective treatments.
Protein Name: Ferritin Heavy Chain Like 17
The "FTHL17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FTHL17 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
FTL | FTLP16 | FTLP2 | FTLP3 | FTLP7 | FTMT | FTO | FTO-IT1 | FTOP1 | FTSJ1 | FTSJ3 | FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3 | GAB4 | GABA(A) receptor | GABARAP | GABARAPL1 | GABARAPL2 | GABARAPL3 | GABBR1 | GABBR2 | GABPA | GABPAP | GABPB1 | GABPB1-AS1 | GABPB1-IT1 | GABPB2 | GABRA1 | GABRA2 | GABRA3
